Celgene develops patent portfolio for anti-CD47 therapeutic antibodies
Client(s) Celgene Corporation
Jones Day represented Celgene Corporation in the development of a portfolio of patents directed to anti-CD47 therapeutic antibodies.
Cases & Deals
Before sending, please note:
Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.